White blood cell (WBC) ? 50 × 10^3/?L
White blood cell count (WBC) >= 2,000/mcL; must be obtained within 28 days prior to registration
White Blood Cell Count (WBC) Criteria\r\n* Age 1-9.99 years: WBC >= 50 000/uL \r\n* Age 10-30.99 years: Any WBC \r\n* Age 1-30.99 years: Any WBC with:\r\n** Testicular leukemia\r\n** CNS leukemia (CNS3)\r\n** Steroid pretreatment
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Circulating white blood cell (WBC) count must not be above 20 x10^9/L within 7 days prior to first dose of study agent\r\n* Patients with WBC count above 20 x 10^9/L may be eligible if they start steroids or hydroxyurea per institutional guidelines, but they must discontinue before day 1 of study drug
White blood cell (WBC) count ? 3 × 10e3/µL
White blood cell (WBC) >= 2.0 x 10^9/L
COHORT 1: White blood cell (WBC) count =< 30,000 /mcL within 14 days of treatment initiation\r\n* NOTE: Hydroxyurea/leukapheresis use is allowed to meet this criterion
COHORT 2: White blood cell (WBC) count =< 30,000 /mcL within 14 days of treatment initiation\r\n* NOTE: Hydroxyurea/leukapheresis use is allowed to meet this criterion
White blood cell (WBC) >= 2,000/mm^3, performed within 14 days of treatment initiation
WBC =< 3 x 10^9/L
White blood cell (WBC) >= 3,000/mcL
White Blood Cell Count (WBC) > 3,000/µL
WBC ? 3.0 x 10e9/L
White blood cell (WBC) >= 3000/mcl
White blood cell count (WBC) < 2,000/µL
White Blood Cell (WBC) ?2000/?L (?2 x 10^9/L)
White blood cell (WBC) > 2,000/mcL
White blood cell (WBC) count >= 3,000/mcL
Normal white blood cell count (WBC) (> 3000/mm^3)
White blood cell count (WBC) >= 3.0 K/mm^3
white blood cell (WBC)count >= 3,000/mm3.
Normal white blood cell (WBC) (> 3000/mm^3)
Within 14 days of randomization: White blood cell (WBC) count >= 3 x 10^9/L
White blood cell (WBC) >= 3000/mm^3
White blood cell (WBC) count >= 3 × 10^9/L.
White blood cell (WBC) >= 3000/mm^3
White blood cell (WBC) < 3,500/mm^3
White blood cell (WBC) count >= 3 x 10^9/L
White blood cell (WBC) count >= 3 x 10^9/L (in absence of blood transfusion).
White blood cell (WBC) ? 1,500/mcL
Patients receiving other active treatment for their myeloid malignancy including investigational agents with the exception of hydrea for white blood cell (WBC) control
White blood cell (WBC) > 2,000/dl (or absolute neutrophil count [ANC] > 1,000)
Within 28 days prior to administration of study treatment: White blood count (WBC) > 3 x 10^9/L
Patients with white blood cell (WBC) > 30,000 are not eligible to start therapy; however, it is permissible to use glucocorticoids and/or hydroxyurea to diminish peripheral WBC to less than 30,000 provided these agents are stopped at least 24 hours prior to the first dose of MLN0128 (TAK-228)
White blood cell count (WBC) >= 3,000/mm^3
White blood cell count (WBC) >= 2.5 k/mm^3
White blood cell (WBC) >= 3 x 10^9/L.
White blood cell (WBC) < 2.0 x 10^9/L (or absolute neutrophil count < 1000)
Total white blood cell count (WBC) >= 3000/mm^3
White blood cell (WBC) >= 3.0 x 10^9/L
white blood cell count (WBC) ? upper limit of normal (ULN);
White blood count (WBC) >= 2000/mcL, performed within 14 days of protocol registration
White blood cell (WBC) >= 3000/mm^3 obtained =< 7 days prior to registration
White blood cell (WBC) > 3000/mm^3, within 28 days prior to registration
White blood cell (WBC) < 2,000/mm^3
White blood cell (WBC) >= 3,000/mcL
White blood cell (WBC) within 10% of upper and lower limit of normal range of test
White blood cell (WBC) >= 2000/mm^3
Within 14 days of registration: White blood cell (WBC) > 3 x 10^9/L
White blood cell (WBC) > 50,000/mcL
White blood cell (WBC) count >= 3,000/mm^3 obtained =< 14 days prior to registration
White blood cell count (WBC) > 3 x 10^9/L
Disease status allows delay of additional anti-leukemia therapy for the duration of the study (hydroxyurea is allowed for control of white blood cell count [WBC] throughout study)
White blood cell (WBC) >= 3000/mm^3
White blood cell count (WBC) ? 3.0 x 109/L
White blood cell count (WBC) >= 2500/mm^3
White blood cell (WBC) of 2,000 per microliter (mcL)
White blood cell count (WBC)\t>= 2,000 /mcL
White blood cell (WBC) >= 3000/mm^3
White blood cell count (WBC) >= 2.0 x 10^9/L
White blood cell (WBC) >= 3,000/mm3
White blood cell count (WBC) > 3000 within 30 days of consent
White blood cell (WBC) > 3000 within 45 days of consent
White blood cell (WBC) > 3.0 x 10^9/L within 14 days of study entry
White blood cell (WBC) < 2,500/mm^3
White blood cell count (WBC) >= 3,000/mm^3
White blood cell (WBC) > 2,000/dl or
White blood cell (WBC) > 2000/mm^3
a. WBC > 3,000/µL
White blood cell count (WBC) > 4000/mm^3
White blood cell (WBC) < 4,000
White blood cell (WBC) with differential greater than 3,000/ml
White blood cell (WBC) >= 3.0 x 10^9/L (performed within 14 days prior to registration)
White blood cell count (WBC) > 3,000/mm^3
White blood cell (WBC) count >= 3,500/mm^3 within 7 days prior to starting treatment, OR
Bone marrow function: white blood cell (WBC) < 4,000/µl; platelet count < 100,000 mm3; neutrophil count < 1,500/mm3.
White blood cell (WBC) count 3,000/mL
Hemoglobin level greater than (>) 10 gram per deciliter (g/dL) (following blood transfusion is acceptable) and normal white blood cell (WBC) and neutrophil counts (elevated WBC/absolute neutrophil count [ANC] attributed to steroid treatment is acceptable)
White blood cell count (WBC) >= 3.5K/mm^3
White blood cell (WBC) ? 3000/mm^3
White blood cell count (WBC) t ? 2.5 x 109/L (2500/µL)
Within 14 days prior to first dose of study drug treatment: White blood cell (WBC) >= 2.5 and =< 15.0 x 109/L
White blood cell (WBC) >= 3000/mm3
Obtained within 30 days prior to registration: White blood cell (WBC) >= 2 k/mm^3
White blood cell count (WBC) >= 3 x 10^9/L
White Blood Cell count (WBC) < 4,000/µL
White blood cell (WBC) >= 4000/ml
White blood cell (WBC) count >= 50,000 on hydroxyurea
White blood cell (WBC) of 3000 per mcL
White blood cell (WBC) > 3,000/mcL or
White blood cell (WBC) > 3,000/mm^3
White blood cell (WBC) >= 3,000
White blood count (WBC) > 2.5 x 10^9/L
WBC ?3,000/µl
Total white blood cell count (WBC) > 2000/mcL
Absolute White blood cell (WBC) count ? 15 × 109/L (NOTE: Hydroxyurea is not allowed to attain a WBC count ? 15 x 109/L).
White blood count (WBC) >= 3000/mm^3
WBC ? 2500/?L
White blood cell (WBC) >= 3,000/mm^3
White blood cell (WBC) count >= 3.0 x 10^9/L
White blood cell (WBC) count >= 3.0 x 10^9/L
White blood cell (WBC) count >= 3.0 x 10^9/L
White blood count (WBC) >= 3,000/mm^3
White blood cell count (WBC) >= 4,000/ml
White blood cell (WBC) count ? 3 × 10e3/µL
White blood cell count (WBC) >= 3,000/mm^3
White blood cell (WBC) >= 3,000/mcL
Total white blood cell (WBC) count >= 3000/mm^3
White blood cell (WBC) >= 3,000/mcL
White blood cell (WBC) >= 3000/mm^3
White blood cell (WBC) >= 2000/mm^3
White blood cell (WBC) count >= 3.0 x 10^9/L
White blood cell (WBC) = 2500 mm^3
White blood cell (WBC) <2,000/mm3
White blood cell (WBC) >= 3000/mm^3
EXPANSION COHORT ONLY: White blood cell (WBC) >= 3,00/mm^3
White blood count (WBC) >= 3,000/mm^3
White blood count (WBC) >= 3000/mm^3 (part 1 & 2)
White blood cell (WBC) > 1000/mm^3
White blood cell (WBC) > 2000/mm^3
White blood cell count (WBC) >= 3000/mm^3
White blood cell (WBC) >= 2,000/mm^3
White blood cell count (WBC) >= 3000/mm^3
While blood cell (WBC) ? 3.0
While blood cell (WBC) < 2.0 x 10^9/L
WBC ? 1.5 X10³/µL
White blood cell (WBC) ? 3,000/microL
White blood cell (WBC) < 2000/mcl
White blood cell (WBC) ? 4000/µL (? 4.0 x 103/µL)
They should have normal blood counts with a white blood cell (WBC) count of more than or equal to 3000/mm^3
White blood cell (WBC) >= 2 K/microliter should be obtained with 28 days prior to randomization
White blood cell count (WBC) >= 3.0 x 10^9/L
White blood cell (WBC) count >= 3,500/mm^3
White blood cell (WBC) >= 3.0 x 10^9/L
Total white blood cell count (WBC) >= 2.5 x 10^3/mm^3
White blood cell count (WBC) should be lower than 30,000/mm^3 prior to initiation of cabozantinib (patients who are otherwise medically eligible for enrollment but have a WBC above 30,000/mm^3 are allowed concurrent treatment with hydroxyurea and/or 6-mercaptopurine to stabilize the WBC during the first 15 days of therapy; in these situations, hydroxyurea and/or 6-mercaptopurine will be discontinued once WBC is below 10,000/mm^3, and can be re-started if WBC again rises above 30,000/mm^3 during the first 15 days of therapy of the first cycle)
White blood cell count (WBC) >= 2.0
White blood cell count (WBC) >= 2,000
White blood cell (WBC) >= 3000/mm^3
White blood count (WBC) >= 2.0 g/dL
White blood cell (WBC) >= 3,000/mm^3
Total white blood cell count (WBC) ? 3000/µl, or absolute neutrophil count (ANC) ? 1000/µl
A white blood cell (WBC) count <3 × 109/L, and / or platelet count <100 × 109/L if not due to hypersplenism.
White blood cell count (WBC) at initiation of treatment =< 10,000/L\r\n* If WBC is > 10,000/L patients may be started on leukapheresis or an appropriate dose of hydroxyurea (to be determined by the investigators), until WBC < 10,000/L, at which time the hydroxyurea will be discontinued for 12 hours prior to enrollment
White blood cell count (WBC) >= 3,000/mcL
Abnormal complete blood count; any of the following\r\n* Platelet count less than 75,000/ml\r\n* Hemoglobin (Hb) level less than 10 gm/dl\r\n* White blood cell (WBC) less than 3.5/ml
White blood cell count (WBC) > 3,000/mm^3
White blood cell count (WBC) < 3500/ml
White blood cell (WBC) >= 3000/mm^3
White blood cell (WBC) >= 3000/mm^3
White blood cell (WBC) >= 2,000
White blood cell (WBC) >= 3 x 10^9/L
White blood cell (WBC) >= 1,500/mcL
White blood cell (WBC) > 3.0
White blood cell (WBC) >= 3,500
White blood cell count (WBC) > 4000/mm^3
White blood cell count (WBC) >= 3.0 K/mm^3
White blood cell (WBC) ? 3,500 x10^9/L
White blood cell (WBC) >= 3,500/mm^3
Leukocytes (white blood cell [WBC]) >= 3,000/microliter
White blood cell (WBC) >= 3000/mm^3 within 90 days of enrollment
White blood cell (WBC) < 2.5
White blood cell (WBC) > 2.5 B/L (10^9/L)
Absolute WBC (white blood cell) count ? 20 x 109/L
White blood cell (WBC) >= 3.0 x 109/L
White blood cell (WBC) >= 3000/mm^3
White blood cell (WBC) within normal limits
White blood cell (WBC): 3000 – 10,000
White blood cell (WBC) count ? 20 x 10E3/µL
WBC < 3000/?L
White blood cell (WBC) >= 4000 mm^3 or granulocyte count at least 2,000/mm^3
progressive leukocytosis, defined as increasing white blood cell (WBC) count on at least 2 consecutive evaluations, at least 2 weeks apart and doubling from the nadir to ?20000/?L or absolute increase in WBC by ?50000/?L above the post-treatment nadir
Total White Blood Cell count (WBC) < 25 x 109/L prior to first infusion. Prior or concurrent treatment with hydroxyurea to achieve this level is allowed.
